Samuel et al.[8] reported that in colorectal and prostate cancer cells, the therapeutic effects of drug in combination with Quercetin were influenced by the effective doses and the p53 status of the cells (the combination of 5-Fu with up to 6 μM Quercetin promoted cologenic survival in p53 null cells while 50 μM Quercetin acted opposite role in p53 wild type cells). This evidence concerns the gene TP53 and prostate carcinoma.